title: Redox potential measurements of the Mycobacterium tuberculosis heme protein KatG and the isoniazid-resistant enzyme KatG(S315T): insights into isoniazid activation.
abstract: Mycobacterium tuberculosis KatG is a multifunctional heme enzyme responsible for activation of the antibiotic isoniazid. A KatG(S315T) point mutation is found in >50% of isoniazid-resistant clinical isolates. Since isoniazid activation is thought to involve an oxidation reaction, the redox potential of KatG was determined using cyclic voltammetry, square wave voltammetry, and spectroelectrochemical titrations. Isoniazid activation may proceed via a cytochrome P450-like mechanism. Therefore, the possibility that substrate binding by KatG leads to an increase in the heme redox potential and the possibility that KatG(S315T) confers isoniazid resistance by altering the redox potential were examined. Effects of the heme spin state on the reduction potentials of KatG and KatG(S315T) were also determined. Assessment of the Fe(3+)/Fe(2+) couple gave a midpoint potential of ca. -50 mV for both KatG and KatG(S315T). In contrast to cytochrome P450s, addition of substrate had no significant effect on either the KatG or KatG(S315T) redox potential. Conversion of the heme to a low-spin configuration resulted in a -150 to -200 mV shift of the KatG and KatG(S315T) redox potentials. These results suggest that isoniazid resistance conferred by KatG(S315T) is not mediated through changes in the heme redox potential. The redox potentials of isoniazid were also determined using cyclic and square wave voltammetry, and the results provide evidence that the ferric KatG and KatG(S315T) midpoint potentials are too low to promote isoniazid oxidation without formation of a high-valent enzyme intermediate such as compounds I and II or oxyferrous KatG.
authors.affiliation: Department of Biochemistry and Molecular Biology and Section of Hematology Research, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: N L
authors.initials: NL
authors.lastname: Wengenack
authors.forename: H
authors.initials: H
authors.lastname: Lopes
authors.forename: M J
authors.initials: MJ
authors.lastname: Kennedy
authors.forename: P
authors.initials: P
authors.lastname: Tavares
authors.forename: A S
authors.initials: AS
authors.lastname: Pereira
authors.forename: I
authors.initials: I
authors.lastname: Moura
authors.forename: J J
authors.initials: JJ
authors.lastname: Moura
authors.forename: F
authors.initials: F
authors.lastname: Rusnak
mesh_terms: D019943:Amino Acid Substitution / Q000235:genetics; D000995:Antitubercular Agents / Q000494:pharmacology*; D001426:Bacterial Proteins; D004352:Drug Resistance, Microbial; D004789:Enzyme Activation / Q000187:drug effects / Q000235:genetics; D005609:Free Radicals / Q000378:metabolism; D006420:Hemeproteins / Q000235:genetics / Q000378:metabolism*; D007538:Isoniazid / Q000494:pharmacology*; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000201:enzymology*; D010084:Oxidation-Reduction / Q000187:drug effects; D010544:Peroxidases / Q000235:genetics / Q000378:metabolism*; D011199:Potentiometry; D012694:Serine / Q000235:genetics; D012966:Sodium Cyanide / Q000494:pharmacology; D013053:Spectrophotometry; D013912:Threonine / Q000235:genetics
chemical_list: D000995:Antitubercular Agents; D001426:Bacterial Proteins; D005609:Free Radicals; D006420:Hemeproteins; D013912:Threonine; D012694:Serine; D010544:Peroxidases; C076136:catalase HPI; D012966:Sodium Cyanide; D007538:Isoniazid